Advertisement
Singapore markets closed

  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     

  • S&P 500

    5,085.01
    +14.46 (+0.29%)
     

  • Dow

    38,467.65
    -36.04 (-0.09%)
     

  • Nasdaq

    15,813.98
    +117.34 (+0.75%)
     

  • Bitcoin USD

    66,132.20
    -156.95 (-0.24%)
     

  • CMC Crypto 200

    1,428.05
    +3.95 (+0.28%)
     

  • FTSE 100

    8,072.43
    +27.62 (+0.34%)
     

  • Gold

    2,333.10
    -9.00 (-0.38%)
     

  • Crude Oil

    82.96
    -0.40 (-0.48%)
     

  • 10-Yr Bond

    4.6380
    +0.0400 (+0.87%)
     

  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     

  • Jakarta Composite Index

    7,174.53
    +63.72 (+0.90%)
     

  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

3 Things About CRISPR Therapeutics That Smart Investors Know

Alex Carchidi, The Motley Fool
·3-min read
3 Things About CRISPR Therapeutics That Smart Investors Know

It's easy to see why investors might assume that early-stage gene-editing companies like CRISPR Therapeutics (NASDAQ: CRSP) are too inscrutable to approach. In fact, smart investors know (at least) three key things about this business, and you should too -- especially if you're considering purchasing shares sometime soon. CRISPR has a few partners, but its most important one by far is Vertex Pharmaceuticals (NASDAQ: VRTX).

Continue reading